Salmeterol/fluticasone propionate: A review of its use in the treatment of chronic obstructive pulmonary disease

Drugs

Volumn 67, Issue 16, 2007, Pages 2383-2405

  Keating, Gillian M ^a   McCormack, Paul L ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Drug Evaluations; Chronic obstructive pulmonary disease; Salmeterol fluticasone propionate, general

Indexed keywords

ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; KETOCONAZOLE; PLACEBO; RITONAVIR; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BACKACHE; BRONCHITIS; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DATA BASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; ECG ABNORMALITY; EMBASE; ENDOCRINE DISEASE; FORCED EXPIRATORY VOLUME; HEADACHE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOADRENALISM; INHALER; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; OSTEOPOROSIS; PNEUMONIA; REVIEW; RHINOPHARYNGITIS; SINUSITIS; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 36049030078     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767160-00006     Document Type: Review

References (80)

1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechansims. Eur Respir J 2003 Oct; 22 (4): 672-88
2. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27 (2): 397-412
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176 (6): 532-55
4. Rodríguez-Roisin R. The airway pathophysiology of COPD: implications for treatment. COPD 2005 Jun; 2: 253-62
5. Agusti AGN. COPD, a multicomponent disease: implications for management. Respir Med 2005 Jun; 99 (6): 670-82
6. Dransfield MT, Bailey WC. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. Expert Opin Pharmacother 2004 Aug; 5 (8): 1815-26
7. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination: lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781-91
8. Tay HL, Armoogum N, Tan LKS. Nasal mucociliary clearance and salmeterol. Clin Otolaryngol 1997; 22: 68-70
9. Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007 Sep; 12 (5): 732-9
10. Barnes NC, Qiu Y-S, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006 Apr 1; 173 (7): 736-43
11. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax. Epub 2007 Jun 8
12. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 Oct 1; 170 (7): 760-5
13. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21: 86-94
14. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995 May; 89: 357-62
15. Cazzola M, Santus P, Di Marco F, et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med 2003 May; 97 (5): 453-7
16. Cazzola M, Santangelo G, Piccolo A. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994 Apr; 7 (2): 103-7
17. GlaxoSmithKline. Advair Diskus® 100/50, 250/50, 500/50 prescribing information [online]. Available from URL: http://www.gsk.com/products/advair_us. htm [Accessed 2007 Jul 30]
18. Buchwald A, Hochhaus G. Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy. Int J Clin Pharmacol Ther 1998 Dec; 36 (12): 652-60
19. Sin DD, Man SFP. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 2006 Mar 8; 533 (1-3): 28-35
20. Sekut L, Champion BR, Page K, et al. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995; 99 (3): 461-6
21. 2-agonists and corticosteroids. FASEB J 2001 Jan; 15: 261-9
22. Proud D, Reynolds CJ, Lichtenstein LM, et al. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998 Jul; 28 (7): 868-75
23. Kanthakumar K, Cundell DR, Johnson M, et al. Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin. Br J Pharmacol 1994; 112: 493-8
24. Piatti G, Ambrosetti U, Santus P, et al. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol Res 2005 Feb; 51 (2): 165-8
25. Sin DD, Man SFP. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulm Med 2007 Mar; 13 (2): 90-7
26. Mollmann H, Wagner M, Krishnaswami S, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol 2001; 41: 1329-38
27. Thorsson L, Edsbäcker S, Källen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. Br J Clin Pharmacol 2001; 52: 529-38
28. 2-agonists and corticosteroids on tumor necrosis factor (TNF)-α-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000; 23 (1): 79-85
29. Pace E, Gagliardo R, Melis M, et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol 2004 Nov; 114 (5): 1216-23
30. Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 2003 Jul; 112 (1): 72-8
31. 2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997 Feb; 155 (2): 704-10
32. sα protein expression in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000 May; 278 (5): L1101-6
33. 2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99-106
34. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999 Jan 8; 274 (2): 1005-10
35. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005 Sep 15; 172 (6): 704-12
36. Haque RA, Torrego A, Essilfie-Quaye S, et al. Effect of salmeterol and fluticasone on glucocorticoid receptor translocation in sputum macrophages and peripheral blood mononuclear cells from patients with chronic obstructive pulmonary disease [abstract]. Proc Am Thoracic Soc 2006 Apr; 3 Suppl.: A848
37. Vestbo J, Pauwels R, Anderson JA, et al. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005 Apr; 60 (4): 301-4
38. Dowling RB, Johnson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11: 86-90
39. Dowling RB, Johnson M, Cole PJ, et al. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999; 14: 363-9
40. Mehta RS, Kathman SJ, Daley-Yates PT, et al. Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol/fluticasone propionate 50/500mg and the individual components [abstract]. Am J Respir Crit Care Med 2007 Apr; 175 Suppl.: 127
41. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356 (8): 775-89
42. Singh SD, Whale C, Hatton A, et al. Comparison of the pharmacokinetics (PK) of inhaled fluticasone propionate (FP) in patients with chronic obstructive pulmonary disease (COPD) and healthy subjects [abstract]. Am J Rep Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A281
43. Daley-Yates PT, Harker AJ, Taylor S, et al. Plasma protein binding (PPB) of corticosteroids (CS): reappraisal of its significance in systemic pharmacological activity [abstract no. 13]. J Allergy Clin Immunol 2005 Feb; 115 (2 Suppl. 1): S4
44. Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 2002; 41 (1): 19-30
45. Allen & Hanburys. Seretide 100, 250, 500 Accuhaler [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2007 Sep 26]
46. Manchee GR, Barrow A, Kulkarni S, et al. Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab Dispos 1993; 21 (6): 1022-8
47. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003 Sep; 124 (3): 834-43
48. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 Jan 15; 175 (2): 144-9
49. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003 Feb 8; 361 (9356): 449-56
50. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 Oct 15; 166 (8): 1084-91
51. Celli B, Ferguson GT, Anderson JA, et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [abstract]. Am J Respir Crit Care Med 2007 Apr; 175 Suppl.: A763
52. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. Epub 2007 Oct 4
53. Make B, Hanania NA, ZuWallack R, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005 May; 27 (5): 531-42
54. Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004; 3 (3): 173-81
55. Cazzola M, Noschese P, Centanni S, et al. Salmeterol/fluticasone propionate in a single inhaler device versus theophylline + fluticasone proionate in patients with COPD. Pulm Pharmacol Ther 2004; 17: 141-5
56. Singh D, Brooks J, Hagan G, et al. Superiority of the 'triple' therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD [abstract]. 17th Annual Congress of the European Respiratory Society; 2007 Sep 15-19; Stockholm
57. Cazzola M, Andò F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007; 20 (5): 556-61
58. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007 Apr 17; 146 (8): 545-55
59. Wouters EFM, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005 Jun; 60 (6): 480-7
60. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 Apr 1; 169 (7): 855-9
61. de Vries F, van Staa TP, Bracke MSGM, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25: 879-84
62. Glick H, Briggs A, Lozano-Ortega G, et al. Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [abstract]. Am J Respir Crit Care Med 2007 Apr; 175 Suppl.: A763
63. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619-37
64. Halpin DMG, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thoracic Soc 2006; 3 (7): 619-23
65. American Thoracic Society and European Respiratory Society. Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease [online]. Available from URL: http://www.thoracic.org/COPD/default.asp [Acessed 2007 Jul 27]
66. Calverley PMA, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD 2006 Dec; 3 (4): 233-42
67. Agustí AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-60
68. ClinicalTrials.gov. Can Advair and Flovent reduce systemic inflammation related to chronic obstructive pulmonary disease (COPD)? A multi-center randomized controlled trial [online]. Available from URL: http://clinicaltrials. gov [Accessed 2007 Aug 16]
69. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002 Oct; 20 (4): 819-25
70. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2 (1): 67-74
71. Mapel DW, Nelson LS, Lydick E, et al. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 2007 Jun; 4 (2): 127-34
72. Mapel DW, Hurley JS, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006; 100: 595-609
73. Rabe KF. Treating COPD; the TORCH trial, p values, and the dodo. N Engl J Med 2007 Feb 22; 356 (8): 851-4
74. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005; 2 (4): 272-81
75. Meinke L, Chitkara R, Krishna G. Advances in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007; 8 (1): 23-37
76. GlaxoSmithKline. GSK receives decision from FDA on Advair 500/50 for COPD [media release]. Available from URL: http://www.gsk.com [Accessed 2007 Aug 16]
77. Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005 Oct; 50 (10): 1304-12
78. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81
79. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-9
80. 2-agonist and inhaled corticosteroid combination therapy in COPD. COPD 2006 Sep; 3: 163-71